Allogene Therapeutics Inc
ALLO
Get informed when a big investor buys or sells
+ FollowMarket Cap$693.76M
Close$
$-0.14
107.2% downside
Current Fair Value
107.2% downsideOvervalued by 107.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $693.76 Million |
|---|---|
| Enterprise Value | $725.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.87 |
| Beta | 0.46 |
| Outstanding Shares | 240,290,782 |
Return
| Return on Equity | -37.94% |
|---|---|
| Return on Assets | -30.08% |
| Return on Invested Capital | -36.91% |
Valuation & Multiples
| P/E Ratio | -2.61 |
|---|---|
| PEG | 16.09 |
| Price to Sales | - |
| Price to Book Ratio | 1.98 |
| Enterprise Value to Revenue | 156.36 |
| Enterprise Value to EBIT | -3.79 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$2,500
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 44.38% |
|---|---|
| Total Calls | 2,000▼ 99.28% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 28.41%▼ 48.22% |
|---|---|
| Total Invested | $142.26M▼ 68.01% |
| Investors Holding | 70▼ 143.00% |
ESG Score
No data